PMID- 29082587
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20181202
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 31
IP  - 1
DP  - 2018 Jan
TI  - Effectiveness and safety of polidocanol for the treatment of hemangiomas and 
      vascular malformations: A meta-analysis.
LID - 10.1111/dth.12568 [doi]
AB  - A meta-analysis was conducted to investigate the efficacy and safety of 
      polidocanol versus other conventional therapies in treating hemangiomas (HMs) and 
      vascular malformations (VMs). Literature search was conducted in the Cochrane, 
      Embase, PubMed, Web of Science, CNKI, CBM, VIP, and WanFang databases until March 
      5, 2017. A meta-analysis was conducted using Revman 5.3 software. A total of 19 
      randomized controlled trials (RCTs) involving 1,514 participants met the 
      inclusion criteria. Regarding the effectiveness, statistically significant 
      differences were observed between polidocanol and all the independent treatments 
      (p = .006), but not between polidocanol and pingyangmycin (p = .16). Combination 
      therapy of polidocanol with any other conventional treatments (p = .0001), 
      pingyangmycin (p = .005) or hemoclip (p = .008) elicited a better response 
      compared to treatment with these treatments independently. A meta-analysis on the 
      risk of adverse events (AEs) showed a lower risk for polidocanol versus other 
      treatments, for example, all the conventional treatments used independently 
      (p < .00001) and pingyangmycin (p < .00001). Combination therapy of polidocanol 
      with pingyangmycin also yielded a significantly lower risk of AEs (p < .00001). 
      Polidocanol is at least as effective as other conventional therapies on HMs and 
      VMs (especially venous malformations). The former is much safer. Combining its 
      use with other treatments may produce excellent results. Our study provides 
      strong evidence supporting the use of polidocanol for HMs and VMs.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Gao, Zhi
AU  - Gao Z
AUID- ORCID: 0000-0002-3817-8037
AD  - Pharmacy Department, Plastic Surgery Hospital (Institute), Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Shijingshan District, Beijing 
      100144, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Pharmacy Department, Plastic Surgery Hospital (Institute), Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Shijingshan District, Beijing 
      100144, China.
FAU - Li, Wei
AU  - Li W
AD  - Pharmacy Department, Plastic Surgery Hospital (Institute), Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Shijingshan District, Beijing 
      100144, China.
FAU - Shi, Chen
AU  - Shi C
AD  - Pharmacy Department, Plastic Surgery Hospital (Institute), Chinese Academy of 
      Medical Sciences and Peking Union Medical College, Shijingshan District, Beijing 
      100144, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20171030
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Sclerosing Solutions)
RN  - 0AWH8BFG9A (Polidocanol)
RN  - 11056-06-7 (Bleomycin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 5DY91Y7601 (bleomycetin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - Bleomycin/analogs & derivatives/therapeutic use
MH  - Chi-Square Distribution
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Hemangioma/pathology/*therapy
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Polidocanol
MH  - Polyethylene Glycols/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Sclerosing Solutions/*administration & dosage/adverse effects
MH  - Sclerotherapy/adverse effects/*methods
MH  - Treatment Outcome
MH  - Vascular Malformations/diagnosis/*therapy
MH  - Young Adult
OTO - NOTNLM
OT  - hemangiomas
OT  - polidocanol
OT  - vascular malformations
EDAT- 2017/10/31 06:00
MHDA- 2018/09/25 06:00
CRDT- 2017/10/31 06:00
PHST- 2017/07/20 00:00 [received]
PHST- 2017/09/28 00:00 [revised]
PHST- 2017/10/02 00:00 [accepted]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2017/10/31 06:00 [entrez]
AID - 10.1111/dth.12568 [doi]
PST - ppublish
SO  - Dermatol Ther. 2018 Jan;31(1). doi: 10.1111/dth.12568. Epub 2017 Oct 30.